Pagani O, Regan MM, Fleming GF, et al. Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR+) early breast cancer (BC): Update of the combined TEXT and SOFT trials. SABCS 2017, GS4-02.
Sneller starten met behandeling niet geassocieerd met betere overleving NSCLC
jun 2023 | Immuuntherapie, Longoncologie, Radiotherapie